134 related articles for article (PubMed ID: 29708329)
21. Combined Application of Gadoxetic Acid Disodium-Enhanced Magnetic Resonance Imaging (MRI) and Diffusion-Weighted Imaging (DWI) in the Diagnosis of Chronic Liver Disease-Induced Hepatocellular Carcinoma: A Meta-Analysis.
Li X; Li C; Wang R; Ren J; Yang J; Zhang Y
PLoS One; 2015; 10(12):e0144247. PubMed ID: 26629904
[TBL] [Abstract][Full Text] [Related]
22. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
[TBL] [Abstract][Full Text] [Related]
23. Development of CD44E/s dual-targeting DNA aptamer as nanoprobe to deliver treatment in hepatocellular carcinoma.
Lo CW; Chan CKW; Yu J; He M; Choi CHJ; Lau JYW; Wong N
Nanotheranostics; 2022; 6(2):161-174. PubMed ID: 34976591
[No Abstract] [Full Text] [Related]
24. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis.
Liu X; Jiang H; Chen J; Zhou Y; Huang Z; Song B
Liver Transpl; 2017 Dec; 23(12):1505-1518. PubMed ID: 28886231
[TBL] [Abstract][Full Text] [Related]
25. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
[TBL] [Abstract][Full Text] [Related]
26. Therapy response assessment after radioembolization of patients with hepatocellular carcinoma--comparison of MR imaging with gadolinium ethoxybenzyl diethylenetriamine penta-acetic acid and gadobutrol.
Schelhorn J; Best J; Reinboldt MP; Gerken G; Ruhlmann M; Lauenstein TC; Antoch G; Kinner S
J Vasc Interv Radiol; 2015 Jul; 26(7):972-9. PubMed ID: 25937296
[TBL] [Abstract][Full Text] [Related]
27. Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma?
Kudo M
Oncology; 2010 Jul; 78 Suppl 1():87-93. PubMed ID: 20616589
[TBL] [Abstract][Full Text] [Related]
28. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
Hernandez R; Sun H; England CG; Valdovinos HF; Ehlerding EB; Barnhart TE; Yang Y; Cai W
Theranostics; 2016; 6(11):1918-33. PubMed ID: 27570560
[TBL] [Abstract][Full Text] [Related]
29. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma.
Yoo SH; Choi JY; Jang JW; Bae SH; Yoon SK; Kim DG; Yoo YK; Rha SE; Lee YJ; Jung ES
Ann Surg Oncol; 2013 Sep; 20(9):2893-900. PubMed ID: 23649931
[TBL] [Abstract][Full Text] [Related]
30. Non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of outcomes for early-stage HCC.
Toyoda H; Kumada T; Tada T; Sone Y; Maeda A; Kaneoka Y
Hepatol Int; 2015 Jan; 9(1):84-92. PubMed ID: 25788383
[TBL] [Abstract][Full Text] [Related]
31. Impact of gadoxetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance on the non-invasive diagnosis of small hepatocellular carcinoma: a prospective study.
Granito A; Galassi M; Piscaglia F; Romanini L; Lucidi V; Renzulli M; Borghi A; Grazioli L; Golfieri R; Bolondi L
Aliment Pharmacol Ther; 2013 Feb; 37(3):355-63. PubMed ID: 23199022
[TBL] [Abstract][Full Text] [Related]
32. [A case of hepatocellular carcinoma which could be diagnosed with Gd-EOB-DTPA enhanced MRI].
Ota H; Mikami K; Nagase A; Nagase H; Mukai R; Okada K; Ide Y; Maruyama K; Murata K; Yokouchi H; Tamai M; Kinuta M
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2386-8. PubMed ID: 20037431
[TBL] [Abstract][Full Text] [Related]
33. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging.
Sano K; Ichikawa T; Motosugi U; Sou H; Muhi AM; Matsuda M; Nakano M; Sakamoto M; Nakazawa T; Asakawa M; Fujii H; Kitamura T; Enomoto N; Araki T
Radiology; 2011 Dec; 261(3):834-44. PubMed ID: 21998047
[TBL] [Abstract][Full Text] [Related]
34. Health economic evaluation of Gd-EOB-DTPA MRI vs ECCM-MRI and multi-detector computed tomography in patients with suspected hepatocellular carcinoma in Thailand and South Korea.
Lee JM; Kim MJ; Phongkitkarun S; Sobhonslidsuk A; Holtorf AP; Rinde H; Bergmann K
J Med Econ; 2016 Aug; 19(8):759-68. PubMed ID: 27026278
[TBL] [Abstract][Full Text] [Related]
35. A non-smooth tumor margin in the hepatobiliary phase of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging predicts microscopic portal vein invasion, intrahepatic metastasis, and early recurrence after hepatectomy in patients with hepatocellular carcinoma.
Ariizumi S; Kitagawa K; Kotera Y; Takahashi Y; Katagiri S; Kuwatsuru R; Yamamoto M
J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):575-85. PubMed ID: 21360083
[TBL] [Abstract][Full Text] [Related]
36. Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging.
Watcharin W; Schmithals C; Pleli T; Köberle V; Korkusuz H; Huebner F; Zeuzem S; Korf HW; Vogl TJ; Rittmeyer C; Terfort A; Piiper A; Gelperina S; Kreuter J
Eur J Pharm Biopharm; 2014 May; 87(1):132-41. PubMed ID: 24365328
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic criteria for hepatocellular carcinoma ⩽3 cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging.
Choi SH; Byun JH; Lim YS; Yu E; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
J Hepatol; 2016 May; 64(5):1099-1107. PubMed ID: 26820629
[TBL] [Abstract][Full Text] [Related]
38. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.
Yu MH; Kim JH; Yoon JH; Kim HC; Chung JW; Han JK; Choi BI
Radiology; 2014 Jun; 271(3):748-60. PubMed ID: 24588677
[TBL] [Abstract][Full Text] [Related]
39. Infiltrative hepatocellular carcinoma on gadoxetic acid-enhanced and diffusion-weighted MRI at 3.0T.
Lim S; Kim YK; Park HJ; Lee WJ; Choi D; Park MJ
J Magn Reson Imaging; 2014 May; 39(5):1238-45. PubMed ID: 24136725
[TBL] [Abstract][Full Text] [Related]
40. Multiparametric imaging for detection and characterization of hepatocellular carcinoma using gadoxetic acid-enhanced MRI and perfusion-CT: which parameters work best?
Kurucay M; Kloth C; Kaufmann S; Nikolaou K; Bösmüller H; Horger M; Thaiss WM
Cancer Imaging; 2017 Jun; 17(1):18. PubMed ID: 28659180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
